Sareum today announced the completion of the single ascending dose (SAD) part and the food effect study of its Phase 1a clinical trial for the lead programme SDC-1801. The Phase 1a trial is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p).
These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious ad ....
15 Feb 2024
Hybridan Research: 15/02/2024: Sareum Holdings PLC: Completion of single ascending dose part and food effect study of Phase 1a
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hybridan Research: 15/02/2024: Sareum Holdings PLC: Completion of single ascending dose part and food effect study of Phase 1a
Sareum Holdings plc (SAR:LON) | 27.5 0.9 13.4% | Mkt Cap: 29.4m
- Published:
15 Feb 2024 -
Author:
Emily Liu -
Pages:
5
Sareum today announced the completion of the single ascending dose (SAD) part and the food effect study of its Phase 1a clinical trial for the lead programme SDC-1801. The Phase 1a trial is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p).
These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious ad ....